The popliteal lymph node response to streptozotocin is under type 1, MHC class-I restricted, CD8(+) T-cell control.
The popliteal lymph node (PLN) assay has been proposed to predict the 'autoimmunogenic' potential of xenobiotics. A better understanding of the processes involved in PLN responses is needed to establish the value of this assay for preclinical safety evaluation. In order to determine whether PLN responses involve CD4(+) or CD8(+) T-cells, the effects of streptozotocin (STZ), a prototypic immunotoxic compound, were analyzed after injection into the hind footpad of C57 BL/6 mice and major histocompatibility complex (MHC) class I or II deficient mice. The involvement of type 1 or type 2 cell control on the production of cytokine mRNAs was analyzed in lymph node cells by quantitative RT-PCR, together with the analysis of a wide range of cytokine mRNAs after STZ injection (IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma, IL-2, IL-2 receptor, IL-4, IL-5, IL-6, IL-10 and IL-12). We have found that mice depleted in CD8(+) T-cells did not respond to STZ, whereas mice depleted in CD4(+) T-cells exhibited the expected positive PLN responses, with increased weight and cellularity indices. STZ induced a low production of interleukin (IL)-2 mRNAs, a mild increase in IL-1alpha and IL-6 mRNAs production, and a dramatic increase in IFN-gamma, IL-1beta, TNF-alpha, IL-12 and IL-2 receptor mRNAs, which correlated with positive PLN responses. No effects on IL-4, IL-5 and IL-10 mRNAs synthesis were noted. In CD8(+) T-cell deficient mice, there was no production of IFN-gamma or IL-6 mRNAs. These results suggest that PLN responses to STZ are under the control of type 1, MHC class-I-restricted, CD8(+) T-cells. This is in accordance to the known physiopathology of STZ-induced diabetes. Additional studies are necessary to establish the mechanism of CD8+ T-cell activation.
Choquet-Kastylevsky
G
G
INSERM U503, Toxicologie Médicale et Médecine de l'Environnement, Faculté de Médecine Lyon-RTH Laënnec, 69372, Lyon, France. choquet@laennec.univ-lyonl.fr
Tedone
R
R
Ducluzeau
M T
MT
Kehren
J
J
Nicolas
J F
JF
Descotes
J
J
D000818:Animals; D000911:Antibodies, Monoclonal; D015551:Autoimmunity; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005805:Genes, MHC Class I / Q000276:immunology*; D016898:Interferon-alpha / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D007375:Interleukin-1 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D018664:Interleukin-12 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D007376:Interleukin-2 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D015848:Interleukin-5 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D007717:Knee; D008198:Lymph Nodes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008819:Mice, Nude; D012333:RNA, Messenger / Q000032:analysis; D013047:Specific Pathogen-Free Organisms; D013311:Streptozocin / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D015848:Interleukin-5; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D013311:Streptozocin